---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-064040"
form_type: "8-K"
ticker: "FBLG"
cik: "0001958777"
company_name: "FibroBiologics, Inc."
filed_at: "2026-02-23T23:59:59+00:00"
generated_at: "2026-05-16T01:16:20.562060+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# FibroBiologics stockholders approve reverse stock split and warrant issuances

## Summary
- Reverse stock split approved at ratio between 1:5 and 1:30, with board discretion; 53.6M votes for, 1.3M against.
- Issuance of up to 12.1M shares upon exercise of warrants from Nov 18, 2025 SPA approved (47.9M for, 1.2M against).
- Issuance of up to 4.8M shares upon exercise of warrants from Nov 24, 2025 SPA and related engagement letter approved.
- Issuance of up to 5.6M shares upon exercise of warrants from Dec 14, 2025 SPA and related engagement letter approved.
- Adjournment proposal also passed; all five proposals approved at Feb 20, 2026 special meeting.

## SEC filing metadata
- accession: 0001193125-26-064040
- form_type: 8-K
- ticker: FBLG
- cik: 0001958777
- company_name: FibroBiologics, Inc.
- filed_at: 2026-02-23T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1958777/000119312526064040/0001193125-26-064040-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1958777/000119312526064040/fblg-20260220.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-064040
- JSON: https://secwatch.observer/filing/0001193125-26-064040.json
- Plain text: https://secwatch.observer/filing/0001193125-26-064040.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.